Infectious Disease Control
CGTN: China's COVID-19 vaccines proven safe, effective by trials and data
BEIJING, Jan. 17, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data. The vaccines have helped save people inChina and around the world, which is an irreversible accomplishment and cannot be challenged by denia...
CGTN: China protects lives, shares experience in global COVID-19 fight
BEIJING, Jan. 16, 2023 /PRNewswire/ -- Chinese people are embracing a bustling winter after the country downgraded its COVID-19 management policies. It's a breakthrough in the country's three-year fight against the pandemic, but challenges still lie ahead. Along the journey, China went all out...
Looking Back on Three Years of COVID-19 in China
BEIJING, Jan. 13, 2023 /PRNewswire/ -- A news report from Beijing Review:
CGTN: TCM continues to play significant role in treating COVID-19
BEIJING, Jan. 11, 2023 /PRNewswire/ -- Traditional Chinese Medicine (TCM) has been playing an important role inChina's fight against COVID-19. As China is shifting the focus of its COVID-19 response from preventing infections to protecting people's health and preventing severe cases, the unique...
Global Times: Connected in recognition: Foreign ambassadors signal a welcome for China's optimized, responsible COVID policy
BEIJING, Jan. 11, 2023 /PRNewswire/ -- As of January 8, China downgraded the management of COVID-19 from category A to the less serious category B infectious disease in light of the evolving epidemic. The Chinese government has optimized measures to combat the epidemic in accordance with the soci...
Global Times: 'Zhang Wenhong phenomenon' shows inclusiveness of China's public opinion sphere; policymaking based on science helps nation firmly hold strategic initiative of epidemic fight
BEIJING, Jan. 11, 2023 /PRNewswire/ -- On Friday, China released the 10th edition of the COVID-19 prevention and control protocol. Moreover, starting from Sunday, the country downgraded the management of COVID-19 from Class A to Class B and lifted quarantine requirements for inbound travelers. Th...
CGTN: China downgrades COVID-19 rules as nation readies for normal life
BEIJING, Jan. 9, 2023 /PRNewswire/ -- China put its downgraded COVID-19
measures into force on Sunday as the nation began to resume normal life after
three years of strict pandemic management.
China welcomes first arrivals following downgraded COVID management
BEIJING, Jan. 9, 2023 /PRNewswire/ -- A report from People's Daily: The first flights underChina's new COVID-19 management for international travelers arrived at airports in southChina's Guangdong province on Jan. 8, according to the national customs authority. Over 380 passengers were aboard tw...
Global Times: China shifts COVID policy with necessary conditions
BEIJING, Jan. 5, 2023 /PRNewswire/ -- After three years' hard efforts to keep COVID-19 at bay,China has optimized its virus response and come up with a major shift in its epidemic policy by downgrading COVID management and announcing the reopening of international borders fromJanuary 8, 2023. Glo...
CGTN: China's preparedness for adjusting its COVID-19 policies
BEIJING, Jan. 5, 2023 /PRNewswire/ -- Since China prioritized its COVID-19
response from the dynamic zero-COVID policy, some Western media and
intellectuals have been questioningChina's "preparedness" of making the change.
CGTN: China's dynamic zero-COVID policy sets the foundation for reopening
BEIJING, Jan. 5, 2023 /PRNewswire/ -- China has adjusted its response to COVID-19 prevention and control in recent weeks. It announced it will downgrade COVID-19 management from Class A to Class B infectious disease while resuming passport, visa issuance and easing border-entry policies starting ...
China's optimization of control measures lays solid foundation for COVID-19 response
BEIJING, Jan. 4, 2023 /PRNewswire/ -- A report from People's Daily: Local authorities and relevant departments inChina have been making unremitting efforts recently to ensure the supply of medical resources, satisfy the demand for medicines and focus on the prevention and treatment of high-risk g...
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava inChina in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership ...
CGTN: China monitors coronavirus mutations to adjust COVID-19 response
BEIJING, Jan. 3, 2023 /PRNewswire/ -- With China loosening its COVID-19 restrictions, some experts have expressed concern thatChina's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating. "It is a worry," said CNN, citing William Schaffner, professor at the Divisi...
CGTN: Xi Jinping salutes ordinary people's extraordinary efforts in New Year Address
BEIJING, Jan. 1, 2023 /PRNewswire/ -- From medical professionals to delivery men and women, from community workers to next-door neighbors, ordinary Chinese people are doing their best and lending a hand to help others cope with the latest waves of COVID-19 infections in the country. &amp...
CGTN:How do emergency wards in China cope with increasing COVID patients?
BEIJING, Jan. 3, 2023 /PRNewswire/ -- Ninety-year-old Qu Fucheng was waiting
for his COVID-19 treatment in Wuhan Zhongnan Hospital when his son realized how
crowded the emergency department was.
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
GAITHERSBURG, Md., Dec. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CI...
Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19
* GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load;...
China enters new stage in COVID-19 response
BEIJING, Dec. 29, 2022 /PRNewswire/ -- A news report by China.org.cn on China's COVID-19 response:   Changes are taking place to China's COVID-19 response. Now, efforts are being accelerated across the country to fully reopen the economy, and people are generally no longer requ...
CGTN: Vitality under COVID-19: China's smart ports aid increased throughput
BEIJING, Dec. 29, 2022 /PRNewswire/ -- China's Qingdao Port, a subsidiary of Shandong Port Group and the second-largest foreign trade port in eastChina's Shandong Province, has seen an increase in anchorage rotations of very large container ships, according to China Media Group. The port has han...
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00